ArticleFrontiers in bioscience : a journal and virtual library2007
Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1.
Article in Frontiers in bioscience : a journal and virtual library, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 59 citations in OpenAlex.
- Article
- Regulation of Mesothelial Cell Fate during Development and Human Diseases.International journal of molecular sciences · 2022Review
- Every Beat You Take-The Wilms' Tumor Suppressor WT1 and the Heart.International journal of molecular sciences · 2021Review
- Article
- miR-361-5p Mediates SMAD4 to Promote Porcine Granulosa Cell Apoptosis through VEGFA.Biomolecules · 2020Article
- Clinical development of targeted and immune based anti-cancer therapies.Journal of experimental & clinical cancer research : CR · 2019Review
- Chondrocytes Promote Vascularization in Fracture Healing Through a FOXO1-Dependent Mechanism.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019Article
- Wilms tumor protein-dependent transcription of VEGF receptor 2 and hypoxia regulate expression of the testis-promoting geneThe Journal of biological chemistry · 2017Article
- Hemolytic uremic syndrome as the presenting manifestation of WT1 mutation and Denys-Drash syndrome: a case report.BMC nephrology · 2017Article
- The Androgen Receptor and VEGF: Mechanisms of Androgen-Regulated Angiogenesis in Prostate Cancer.Cancers · 2017Review
- WT1 expression in breast cancer disrupts the epithelial/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel.Scientific reports · 2017Article
- Genome-Wide Analysis of Wilms' Tumor 1-Controlled Gene Expression in Podocytes Reveals Key Regulatory Mechanisms.Journal of the American Society of Nephrology : JASN · 2015Article
- Adrenomedullin Up-regulates the Expression of Vascular Endothelial Growth Factor in Epithelial Ovarian Carcinoma Cells via JNK/AP-1 Pathway.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2015Article
- Mechanisms of transcriptional regulation by WT1 (Wilms' tumour 1).The Biochemical journal · 2014Review
- WT1 regulates angiogenesis in Ewing Sarcoma.Oncotarget · 2014Article
- Early B-cell factor 1 is an essential transcription factor for postnatal glomerular maturation.Kidney international · 2014Article
- Diagnostic utility of WT-1 cytoplasmic stain in variety of vascular lesions.International journal of clinical and experimental pathology · 2014Article
- Resistin promotes the expression of vascular endothelial growth factor in ovary carcinoma cells.International journal of molecular sciences · 2013Article
- Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site.Molecular cancer · 2013Article
- WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia.The Journal of biological chemistry · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Understanding angiogenesis and growth control is central for elucidating prostate tumorigenesis. However, the mechanisms of activation of the angiogenic gene, vascular endothelial growth factor (VEGF) are complex and its regulation in prostate cancer is not well understood. In previous studies, VEGF expression levels were correlated with altered levels of the zinc finger transcription factor, WT1. Since the VEGF promoter has several potential WT1 binding sites and WT1 regulates many growth control genes, here we assessed whether WT1 might also regulate VEGF transcription. Using transfection and DNA binding assays, functional WT1 binding sites were localized within the proximal VEGF promoter. Transfection of the DDS-WT1 (R394W) zinc finger mutant had no significant effect on VEGF-luciferase reporter activity, suggesting that an intact zinc finger DNA binding domain was required. Interestingly, WT1-mediated regulation of VEGF reporter constructs varied in different cell types. In androgen-responsive, LNCaP prostate cancer cells, hormone treatment enhanced WT1-mediated activation of the VEGF promoter constructs. Overall, these results suggest that WT1 transcriptionally regulates VEGF through interaction of its zinc finger DNA binding domain with the proximal GC-rich VEGF promoter. These findings may shed light on the role of WT1 in angiogenesis and prostate cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.